“Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s272. doi:10.25251/skin.7.supp.272.